MedTrace Logo

Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Viral Conjunctivitis

NCT03749317 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 135

Last updated 2025-10-15

No results posted yet for this study

Summary

A Phase 2, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of IVIEW-1201 (1.0% Povidone-Iodine) Gel Forming Ophthalmic Solution Compared to Placebo in the Treatment of Adenoviral Conjunctivitis

Conditions

  • Adenoviral Conjunctivitis

Interventions

DRUG

IVIEW-1201

IVIEW-1201; QID; one drop per eye, four times per day (QID) for 7 days

DRUG

Placebo

Placebo drug; QID; one drop per eye, four times per day (QID) for 7 days

Sponsors & Collaborators

  • IVIEW Therapeutics Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-20
Primary Completion
2024-04-30
Completion
2024-12-31
FDA Drug
Yes

Countries

  • India

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03749317 on ClinicalTrials.gov